Viberzi (eluxadoline) was approved by the FDA on May 27, 2015 as a new option for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
What is irritable bowel syndrome?
Irritable bowel syndrome or IBS is a disorder that affects the large intestine. IBS can be diarrhea- or constipation-predominant, meaning you mostly experience either one or the other. Symptoms can include stomach pain, cramping, bloating, gas, diarrhea, and constipation.
It’s not known exactly what causes IBS, but factors like young age, female gender, genetics, or mental health problems may put a person at greater risk.
When will Viberzi be available?
According to the manufacturer, Actavis, the Viberzi launch is anticipated for the first quarter of 2016.
Will this medication be a controlled substance?
Since Viberzi affects the opioid receptors of the brain, the FDA has recommended that it be classified as a controlled substance. However, the scheduling designation for Viberzi is under review at the moment, and it will be determined before the release in 2016.
What are the side effects associated with Viberzi?
The most common side effects include stomach pain, constipation, and nausea.
Want more information?